The use of bispecific T cell engagers (also known as BiTE) therapies has been increasing to treat patients with blood cancers. However, there are side effects and other factors to consider when deciding on the treatment type, explained Kathy Mooney.
Mooney, clinical program director at Johns Hopkins Hospital and Johns Hopkins Health System, sat down with CURE® at the 49th Annual Oncology Nursing Society Congress to discuss BiTE therapies.
“It’s an intense model of care, especially in the beginning. Its frequent dosing [and] there are harsh side effects that the patients need to be aware of,” Mooney said. Common side effects from BiTE therapy include neurotoxicity (nervous system damage) and cytokine release syndrome, when there is an influx of inflammatory molecules, called cytokines, in the bloodstream. Cytokine release syndrome can be serious and life-threatening if it is not caught early on.
READ MORE: Educated Patient® Multiple Myeloma Summit BiTE and Future Myeloma Directions Presentation
“So, ensuring that they have good social support is probably key to the initial step-up dosing,” Mooney said. Social support is important because it can help look for signs of side effects, transportation assistance and communication with doctors.
Step-up dosing means that a small amount of the drug will be administered at first, and the dosage increases as the treatment progresses.
However, for patients who do not have strong social support at home, Mooney said that does not mean the BiTE therapies are out of the question. She advised these patients to be open with their care teams if this is the case. Assistance programs exist, such as those that can help with lodging or transportation. Additionally, for these patients, maybe it is best to receive BiTE therapy in the inpatient (hospital) setting, rather than outpatient (in a clinic outside of the hospital), Mooney said.
Transcript:
It's an intense model of care, especially in the beginning, it's frequent dosing [and] there are harsh side effects that the patients need to be aware of. So ensuring that they have good social support is probably key to the initial step-up dosing. We need to make sure that they are safe, and that they can be transitioned quickly to care areas when they need that and have somebody looking out for them for any of those signs and symptoms that may occur.
Some of these options are also … long treatment. There's no end date for the treatment. So making sure they're aware that this is going to be an intense therapy for many months, many weeks, and making sure they feel comfortable with the ability to continue that care [is important].
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Social Support Is Key During BiTE Therapy for Blood Cancers
An oncology nurse discusses what patients should know before BiTE therapy, and what they can do if they do not have a social support system.
The use of bispecific T cell engagers (also known as BiTE) therapies has been increasing to treat patients with blood cancers. However, there are side effects and other factors to consider when deciding on the treatment type, explained Kathy Mooney.
Mooney, clinical program director at Johns Hopkins Hospital and Johns Hopkins Health System, sat down with CURE® at the 49th Annual Oncology Nursing Society Congress to discuss BiTE therapies.
“It’s an intense model of care, especially in the beginning. Its frequent dosing [and] there are harsh side effects that the patients need to be aware of,” Mooney said. Common side effects from BiTE therapy include neurotoxicity (nervous system damage) and cytokine release syndrome, when there is an influx of inflammatory molecules, called cytokines, in the bloodstream. Cytokine release syndrome can be serious and life-threatening if it is not caught early on.
READ MORE: Educated Patient® Multiple Myeloma Summit BiTE and Future Myeloma Directions Presentation
“So, ensuring that they have good social support is probably key to the initial step-up dosing,” Mooney said. Social support is important because it can help look for signs of side effects, transportation assistance and communication with doctors.
Step-up dosing means that a small amount of the drug will be administered at first, and the dosage increases as the treatment progresses.
However, for patients who do not have strong social support at home, Mooney said that does not mean the BiTE therapies are out of the question. She advised these patients to be open with their care teams if this is the case. Assistance programs exist, such as those that can help with lodging or transportation. Additionally, for these patients, maybe it is best to receive BiTE therapy in the inpatient (hospital) setting, rather than outpatient (in a clinic outside of the hospital), Mooney said.
Transcript:
It's an intense model of care, especially in the beginning, it's frequent dosing [and] there are harsh side effects that the patients need to be aware of. So ensuring that they have good social support is probably key to the initial step-up dosing. We need to make sure that they are safe, and that they can be transitioned quickly to care areas when they need that and have somebody looking out for them for any of those signs and symptoms that may occur.
Some of these options are also … long treatment. There's no end date for the treatment. So making sure they're aware that this is going to be an intense therapy for many months, many weeks, and making sure they feel comfortable with the ability to continue that care [is important].
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Iopofosine I 131 Is Promising Across Waldenstrom’s Macroglobulinemia Types
Eighty percent of patients with relapsed or refractory Waldenstrom’s macroglobulinemia responded to treatment with iopofosine I 131, researchers found.
Read More
5 Factors Linked to Greater Chance of Polycythemia Vera Progression
Researchers identified five traits that may increase a person’s chance of experiencing polycythemia vera progression.
Read More
Iclusig Leads to Better Responses Than Gleevec in Leukemia Subset
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia had better MRD statuses after receiving Iclusig, compared with Gleevec.
Read More
Survivors May Have Successful Pregnancies After Stem Cell Transplants
Contrary to past research, blood cancer survivors may have safe and successful pregnancies up to 10 years after an allogeneic stem cell transplant.
Read More
My Invisible Losses That Emerge from Cancer
Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.
Read More
Antibody Testing May Decrease Infection Risk in Blood Cancer Survivors
More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.
Read More
Iopofosine I 131 Is Promising Across Waldenstrom’s Macroglobulinemia Types
Eighty percent of patients with relapsed or refractory Waldenstrom’s macroglobulinemia responded to treatment with iopofosine I 131, researchers found.
Read More
5 Factors Linked to Greater Chance of Polycythemia Vera Progression
Researchers identified five traits that may increase a person’s chance of experiencing polycythemia vera progression.
Read More
Iclusig Leads to Better Responses Than Gleevec in Leukemia Subset
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia had better MRD statuses after receiving Iclusig, compared with Gleevec.
Read More
Survivors May Have Successful Pregnancies After Stem Cell Transplants
Contrary to past research, blood cancer survivors may have safe and successful pregnancies up to 10 years after an allogeneic stem cell transplant.
Read More
My Invisible Losses That Emerge from Cancer
Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.
Read More
Antibody Testing May Decrease Infection Risk in Blood Cancer Survivors
More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.
Read More